leukemia

[Sutro Biopharma, Inc.] Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

[Advanced Science] The authors reported an adverse effect of NEAT1, showing that the short isoform, NEAT1_1 suppressed acute myeloid leukemia (AML) development. NEAT1_1 was downregulated in leukemia stem cells and its decreased expression correlated with recurrence in AML patients.

[Bmj Open] Investigators discuss important updates in diagnostic and disease classifications that reflect new understanding of the biology of acute myeloid leukemia, its mutational heterogeneity, some important genetic and environmental risk factors, and new treatment options including cytotoxic chemotherapy, novel targeted agents, and cellular therapies.

[Stem Cell Research & Therapy] Investigators highlight the preclinical and clinical efforts made for addressing the drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T cell malignancies.

[Blood] Scientists discuss the current approach to various linical issues and how emerging novel therapeutics hold promise to advance transplant care for patients with non-malignant diseases.

[Cell Death & Disease] Scientists used next-generation sequencing to explore endogenous miRNAs in chronic myeloid leukemia (CML) patients versus healthy volunteers, and miR-342-5p was identified as the primary target. They found that miR-342-5p was downregulated in CML patients and had a significant inhibitory effect on cell proliferation in CML.